PROCEPT BioRobotics Co. (NASDAQ:PRCT) is Evolutionary Tree Capital Management LLC's 5th Largest Position

Evolutionary Tree Capital Management LLC trimmed its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 12.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 61,118 shares of the company's stock after selling 8,725 shares during the quarter. PROCEPT BioRobotics accounts for approximately 5.0% of Evolutionary Tree Capital Management LLC's holdings, making the stock its 5th biggest holding. Evolutionary Tree Capital Management LLC owned approximately 0.12% of PROCEPT BioRobotics worth $4,921,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. HighTower Advisors LLC bought a new position in PROCEPT BioRobotics during the third quarter valued at $279,000. State Street Corp grew its holdings in PROCEPT BioRobotics by 5.9% during the 3rd quarter. State Street Corp now owns 1,179,514 shares of the company's stock valued at $94,503,000 after purchasing an additional 66,175 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in PROCEPT BioRobotics in the 3rd quarter worth about $1,081,000. Geode Capital Management LLC boosted its position in shares of PROCEPT BioRobotics by 8.2% during the third quarter. Geode Capital Management LLC now owns 1,106,588 shares of the company's stock valued at $88,678,000 after buying an additional 84,244 shares during the period. Finally, Neo Ivy Capital Management bought a new position in shares of PROCEPT BioRobotics during the third quarter valued at approximately $228,000. Institutional investors own 89.46% of the company's stock.

Insider Buying and Selling

In other news, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares of the company's stock, valued at $9,875,374.20. This trade represents a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin Waters sold 733 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares in the company, valued at approximately $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,455 shares of company stock worth $368,322 in the last three months. 17.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on PRCT shares. Morgan Stanley dropped their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Truist Financial decreased their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of "Moderate Buy" and a consensus target price of $91.43.

PROCEPT BioRobotics Stock Up 0.3 %

PROCEPT BioRobotics stock traded up $0.17 during midday trading on Thursday, hitting $52.98. 466,822 shares of the company's stock were exchanged, compared to its average volume of 779,054. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company has a market cap of $2.90 billion, a PE ratio of -27.22 and a beta of 1.09. The firm has a 50-day moving average of $59.75 and a two-hundred day moving average of $75.01.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. As a group, analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).